Hepcidin and ferritin blood level as noninvasive tools for predicting breast cancer
Open accessAbstract
Background Currently used CA15-3 and CEA have found their clinical application particularly in the follow-up of patients with advanced disease. Novel biomarkers are urgent, especially for improving early diagnosis as well as for discriminating between benign and malignant disease.Patients and methods In the present study, we used a proteomic approach based on surface-enhanced laser desorption/ionization-time of flight-mass spectrometry screening with the aim of identifying differentially expressed 2-30 kDa proteins in plasma of patients with malignant (65 cases) and benign (88 cases) breast lesions with respect to 121 healthy controls.Results We found that the most promising SELDI peaks were those corresponding to hepcidin-25 and ferritin light chain. We evaluated the capability of these peaks in predicting malignant and benign breast lesions using the area under the receiver operating characteristic curve (AUC). The results showed a good capacity to predict malignant breast lesions for hepcidin-25 [AUC: 0.82; 95% confidence interval (CI) 0.75-0.90] and ferritin light chain (AUC: 0.86; 95% CI 0.79-0.92). Conversely, a weak and satisfactory capability to predict benign breast lesion was observed for hepcidin-25 (AUC: 0.63; 95% CI 0.41-0.85) and ferritin light chain (AUC: 0.73; 95% CI 0.49-0.97). A significant association between HER2 status and hepcidin-25 was observed and the distribution of transferrin and ferritin were found significantly different in patients with breast cancer when compared with that of controls.Conclusions This study provides evidence that hepcidin and ferritin light chain level in plasma may be of clinical usefulness to predict malignant and benign disease with respect to healthy controls.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Serum concentrations of FT are increased in cancer patients compared to healthy individuals.
“Moreover, serum concentrations of FT are increased in cancer patients compared to healthy individuals [35].”
From Iron as a central player and promising target in cancer progression (2019) · cites this paper as [35]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
(1990) · Choice Reviews Online · doi:10.5860/choice.27-3338 · Cited by 35,305 · see citing works
The meaning and use of the area under a receiver operating characteristic (ROC) curve.
Hanley, J. A., & McNeil, B. J. (1982) · Radiology · doi:10.1148/radiology.143.1.7063747 · Cited by 21,856 · see citing works
Kupper, L. L., Hosmer, D. W., & Lemeshow, S. A. (1990) · Journal of the American Statistical Association · doi:10.2307/2290035 · Cited by 7,690 · see citing works
Nonparametric Statistical Methods
(1999) · Technometrics · doi:10.1080/00401706.1999.10485954 · Cited by 6,117 · see citing works
Flexible regression models with cubic splines
Durrleman, S., & Simon, R. M. (1989) · Statistics in Medicine · doi:10.1002/sim.4780080504 · Cited by 2,701 · see citing works
Nemeth, E., Rivera, S., Gabayan, V., Keller, C., Taudorf, S., Pedersen, B. K., & Ganz, T. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200420945 · Cited by 2,650 · see citing works
Knovich, M. A., Storey, J. A., Coffman, L. G., Torti, S. V., & Torti, F. M. (2008) · Blood Reviews · doi:10.1016/j.blre.2008.08.001 · Cited by 666 · see citing works
Nonparametric Statistical Methods
Ziegel, E. R., Hollander, M., & Wolfe, D. A. (1999) · Technometrics · doi:10.2307/1271371 · Cited by 610 · see citing works
Serum ferritin is derived primarily from macrophages through a nonclassical secretory pathway
Cohen, L. A., Gutierrez, L., Weiss, A., Leichtmann-Bardoogo, Y., Zhang, D.-L., Crooks, D. R., Sougrat, R., Morgenstern, A., Galy, B., Hentze, M. W., et al. (2010) · Blood · doi:10.1182/blood-2009-11-253815 · Cited by 452 · see citing works
Ferroportin and Iron Regulation in Breast Cancer Progression and Prognosis
Pinnix, Z. K., Miller, L. D., Wang, W., D’Agostino, R., Kute, T., Willingham, M. C., Hatcher, H., Tesfay, L., Sui, G., Di, X., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3001127 · Cited by 448 · see citing works
Hou, Y., Zhang, S., Wang, L., Li, J., Qu, G., He, J., Rong, H., Ji, H., & Liu, S. (2012) · Gene · doi:10.1016/j.gene.2012.09.060 · Cited by 210 · see citing works
Artusi, R., Verderio, P., & Marubini, E. (2002) · The International Journal of Biological Markers · doi:10.1177/172460080201700213 · Cited by 209 · see citing works
Self-citationArtusi, R., Verderio, P., & Marubini, E. (2002) · The International Journal of Biological Markers · doi:10.5301/jbm.2008.2127 · Cited by 141 · see citing works
Self-citationIn anemia of multiple myeloma, hepcidin is induced by increased bone morphogenetic protein 2
Maes, K., Nemeth, E., Roodman, G. D., Huston, A., Esteve, F., Freytes, C., Callander, N., Katodritou, E., Tussing-Humphreys, L., Rivera, S., et al. (2010) · Blood · doi:10.1182/blood-2010-03-274571 · Cited by 132 · see citing works
Methods correcting for multiple testing: operating characteristics
Brown, B. W., & Russell, K. E. (1997) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19971130)16:22 · Cited by 118 · see citing works
Anemia in Hodgkin's Lymphoma: The Role of Interleukin-6 and Hepcidin
Hohaus, S., Massini, G., Giachelia, M., Vannata, B., Bozzoli, V., Cuccaro, A., D'Alo', F., Larocca, L. M., Raymakers, R. A. P., Swinkels, D. W., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.6873 · Cited by 110 · see citing works
Involvement of Hepcidin in the Anemia of Multiple Myeloma
Sharma, S., Nemeth, E., Chen, Y.-H., Goodnough, J. B., Huston, A. J., Roodman, G. D., Ganz, T., & Lichtenstein, A. K. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4153 · Cited by 107 · see citing works
Jézéquel, P., Campion, L., Spyratos, F., Loussouarn, D., Campone, M., Guérin‐Charbonnel, C., Joalland, M., André, J., Descotes, F., Grenot, C., et al. (2012) · International Journal of Cancer · doi:10.1002/ijc.26397 · Cited by 85 · see citing works
Multiparametric Analysis of Cell-Free DNA in Melanoma Patients
Salvianti, F., Pinzani, P., Verderio, P., Ciniselli, C. M., Massi, D., GIORGI, V. D., Grazzini, M., Pazzagli, M., & Orlando, C. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049843 · Cited by 65 · see citing works
Self-citationElevation in Inflammatory Serum Biomarkers Predicts Response to Trastuzumab-Containing Therapy
Alkhateeb, A. A., Leitzel, K., Ali, S. M., Campbell‐Baird, C., Evans, M., Fuchs, E., Köstler, W. J., Lipton, A., & Connor, J. R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0051379 · Cited by 35 · see citing works
Breast Density Influences Tumor Subtypes and Tumor Aggressiveness
Kerlikowske, K. M., & Phipps, A. I. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr263 · Cited by 19 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Kell, D. B., & Pretorius, E. (2014) · Metallomics · doi:10.1039/c3mt00347g · Cited by 667 · see citing works
Targeting iron metabolism in drug discovery and delivery
Crielaard, B. J., Lammers, T., & Rivella, S. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.248 · Cited by 352 · see citing works
Iron as a central player and promising target in cancer progression
Jung, M., Mertens, C., Tomat, E., & Brüne, B. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20020273 · Cited by 268 · see citing works
“Moreover, serum concentrations of FT are increased in cancer patients compared to healthy individuals [35].”
BackgroundThe effect of abnormal iron metabolism on osteoporosis
Che, J., Yang, J., Zhao, B., Zhang, G., Wang, L., Peng, S., & Shang, P. (2020) · Biological Trace Element Research · doi:10.1007/s12011-019-01867-4 · Cited by 113 · see citing works
- Authors
- Orlandi, R., De Bortoli, M., Ciniselli, C. M., Vaghi, E., Caccia, D., Garrisi, V., Pizzamiglio, S., Veneroni, S., Bonini, C., Agresti, R., Daidone, M. G., Morelli, D., Camaschella, C., Verderio, P., & Bongarzone, I.
- Affiliations
- Istituto Tumori Bari (IT)
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- Vita-Salute San Raffaele University (IT)
- Corresponding author
- Bongarzone, I.
- ORCID
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2014-02
- Volume
- 25
- Issue
- 2
- Pages
- 352-357
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2124496099
- Cited by
- 74
- References
- 21
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 11 · 2023: 4 · 2022: 8 · 2021: 10 · 2020: 9 · 2019: 6 · 2018: 1 · 2017: 8 · 2016: 5 · 2015: 3 · 2014: 4
- FWCI
- 1.80
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Annals of Oncology (publishedVersion)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- HighWire Press Open Archive (submittedVersion)
- Funders
- Associazione Italiana per la ricerca sul cancro (IG_13208)
- Topics
- Physical Sciences › Chemistry › Spectroscopy › Advanced Proteomics Techniques and Applications
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Keywords
- hepcidin, ferritin light chain, breast cancer, benign breast disease, plasma biomarkers, SELDI-TOF mass spectrometry, proteomic screening, early diagnosis, HER2 status, transferrin, differentially expressed proteins
- MeSH terms
- Adolescent, Adult, Aged, Breast Neoplasms, Female, Ferritins, Humans, Middle Aged, ROC Curve, Biomarkers, Tumor, Case-Control Studies, Early Detection of Cancer, Young Adult, Hepcidins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
